Bavarian Nordic initiates Phase 2 trial

The company has announced the topline results from HIBISCUS, a phase 3 trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD).

Evaxion has announced new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets.

Pfizer and Valneva's Lyme disease vaccine candidate demonstrated strong efficacy in their Phase 3 VALOR trial.

The company has completed preparations and received all regulatory approvals for the VITAL-CML trial.

Diamyd Medical has announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes.

The company has announced initial learnings from the 12-month Expanded Access Program (EAP) with its lead drug candidate CS1 in pulmonary arterial hypertension (PAH).

The company has announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa (HS).